Abstract
Aspergillus flavus was identified as the dominant clinical etiological agent in this study. Given the prevalence of A. flavus in local clinical settings, healthcare providers may face greater challenges when treating patients with invasive pulmonary aspergillosis (IPA).
Introduction
Invasive pulmonary aspergillosis (IPA) is a severe fungal infection that primarily affects immunocompromised individuals. While Aspergillus fumigatus is globally recognized as the most frequent cause of IPA, regional variations in species distribution can significantly impact clinical management. This study investigates the prevalence, virulence, and antifungal susceptibility of Aspergillus species isolated from patients at Jining No. 1 People’s Hospital in Shandong, China, between 2018 and 2022.
Methodology
Researchers analyzed 46 clinical isolates from 45 patients using a polyphasic approach. Species identification was performed using Calmodulin (CaM) gene sequencing, which provides higher resolution than traditional morphological methods.
To assess virulence, the study employed the Galleria mellonella (wax moth) larvae model. This model allows for the observation of survival rates, melanization (an insect immune response), and histopathological changes. Additionally, antifungal susceptibility testing was conducted against six common drugs following CLSI M38-A3 protocols, and clinical blood profiles of IPA patients were compared against healthy controls to identify inflammatory markers.
Results and Discussion
Species Identification and Distribution
Contrary to global trends, Aspergillus flavus was the most prevalent species, accounting for 54.3% of the isolates. This was followed by A. fumigatus (19.6%) and A. awamori (19.6%). The dominance of A. flavus in this region may be linked to local environmental factors, such as agricultural exposure to crops where this species is common.
Morphological and Virulence Profiles
While molecular identification was definitive, the isolates also displayed diverse phenotypic characteristics. Morphological examination on various media revealed distinct growth patterns and pigmentation across the different sections.
In the G. mellonella model, A. flavus demonstrated significantly higher virulence compared to A. niger and A. fumigatus. Larvae infected with A. flavus showed lower survival rates (5%–30% at 24 hours depending on the dose) and a more robust melanization response, indicating a potent immune trigger. Histopathological analysis confirmed extensive tissue damage and hyphal formation in the A. flavus-infected groups.
Antifungal Resistance and Clinical Markers
Antifungal susceptibility testing revealed a concerning trend: 91% of the isolates were resistant to Fluconazole. Resistance was also noted for Micafungin (31%), Amphotericin B (14%), and Terbinafine (14%).
Clinically, IPA patients exhibited a specific inflammatory signature characterized by significantly elevated C-reactive protein (CRP), neutrophils, and monocytes, alongside decreased lymphocyte counts compared to healthy controls. This "blood fingerprint" may assist in the early recognition of invasive fungal infections.
Conclusion
This study highlights A. flavus as a major pathogen in regional IPA cases, exhibiting high virulence and significant resistance to common antifungals. The findings underscore the importance of precise molecular identification and the utility of the Galleria mellonella model in understanding fungal pathogenesis. Future research should focus on the molecular mechanisms driving the high virulence of local A. flavus strains to improve therapeutic outcomes.
Summary updated